Cellular reprogramming: A new technology frontier in pharmaceutical research

Amy Brock, Hui Tong Goh, Binxia Yang, Yu Lu, Hu Li, Yuin Han Loh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

Original languageEnglish (US)
Pages (from-to)35-52
Number of pages18
JournalPharmaceutical Research
Volume29
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Technology
Induced Pluripotent Stem Cells
Drug Discovery
Research
Pharmaceutical Preparations
Stem cells
Pipelines
Testing
Pharmaceutical Research
Cellular Reprogramming
Therapeutics
In Vitro Techniques

Keywords

  • Cellular reprogramming
  • Drug discovery
  • IPSC
  • Pharmaceutical research
  • Stem cells

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Organic Chemistry
  • Molecular Medicine
  • Pharmacology (medical)
  • Biotechnology
  • Pharmacology

Cite this

Cellular reprogramming : A new technology frontier in pharmaceutical research. / Brock, Amy; Goh, Hui Tong; Yang, Binxia; Lu, Yu; Li, Hu; Loh, Yuin Han.

In: Pharmaceutical Research, Vol. 29, No. 1, 01.2012, p. 35-52.

Research output: Contribution to journalArticle

Brock, Amy ; Goh, Hui Tong ; Yang, Binxia ; Lu, Yu ; Li, Hu ; Loh, Yuin Han. / Cellular reprogramming : A new technology frontier in pharmaceutical research. In: Pharmaceutical Research. 2012 ; Vol. 29, No. 1. pp. 35-52.
@article{7b4aa0bae726406d8009a0ea68cf4d2b,
title = "Cellular reprogramming: A new technology frontier in pharmaceutical research",
abstract = "Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.",
keywords = "Cellular reprogramming, Drug discovery, IPSC, Pharmaceutical research, Stem cells",
author = "Amy Brock and Goh, {Hui Tong} and Binxia Yang and Yu Lu and Hu Li and Loh, {Yuin Han}",
year = "2012",
month = "1",
doi = "10.1007/s11095-011-0618-z",
language = "English (US)",
volume = "29",
pages = "35--52",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Cellular reprogramming

T2 - A new technology frontier in pharmaceutical research

AU - Brock, Amy

AU - Goh, Hui Tong

AU - Yang, Binxia

AU - Lu, Yu

AU - Li, Hu

AU - Loh, Yuin Han

PY - 2012/1

Y1 - 2012/1

N2 - Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

AB - Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

KW - Cellular reprogramming

KW - Drug discovery

KW - IPSC

KW - Pharmaceutical research

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84860598122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860598122&partnerID=8YFLogxK

U2 - 10.1007/s11095-011-0618-z

DO - 10.1007/s11095-011-0618-z

M3 - Article

C2 - 22068279

AN - SCOPUS:84860598122

VL - 29

SP - 35

EP - 52

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 1

ER -